The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Targeted therapy using nanotechnology: focus on cancer
Open accessAbstract
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy. Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small molecules, a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biological targets. Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions. However, several obstacles, including difficulty in achieving the optimal combination of physicochemical parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy. In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific molecular targets overexpressed on different cancer cells. In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clinical testing for patients with solid tumors. BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 1×
“55–58 The way forward for the clinical translation of controlled-release polymeric nanoparticles was paved by the seminal work of Langer and Folkman in 1976, which demonstrated the controlled release of macromolecules from biodegradable polymers in a temporal manner.”
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The golden age: gold nanoparticles for biomedicine
Dreaden, E. C., Alkilany, A. M., Huang, X., Murphy, C. J., & El-Sayed, M. A. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15237h · Cited by 3,550
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Gold Nanoparticles for Biology and Medicine
Giljohann, D. A., Seferos, D. S., Daniel, W. L., Massich, M. D., Patel, P. C., & Mirkin, C. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904359 · Cited by 2,356
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Biological applications of gold nanoparticles
Sperling, R. A., Rivera Gil, P., Zhang, F., Zanella, M., & Parak, W. J. (2008) · Chemical Society Reviews · doi:10.1039/b712170a · Cited by 1,799
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
Design of polymeric nanoparticles for biomedical delivery applications
Elsabahy, M., & Wooley, K. L. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15327k · Cited by 1,717
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Nanoshell-Enabled Photothermal Cancer Therapy: Impending Clinical Impact
Lal, S., Clare, S. E., & Halas, N. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar800150g · Cited by 1,625
PEGylated nanoparticles for biological and pharmaceutical applications
Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00226-0 · Cited by 1,588
Hallmarks of Cancer: The Next Generation
Roizen, M. F. (2012) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2012.02.046 · Cited by 1,501
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Multifunctional nanoparticles for multimodal imaging and theragnosis
Lee, D.-E., Koo, H., Sun, I.-C., Ryu, J. H., Kim, K., & Kwon, I. C. (2012) · Chem. Soc. Rev. · doi:10.1039/c2cs15261d · Cited by 1,410
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Polymers for the sustained release of proteins and other macromolecules
LANGER, R., & FOLKMAN, J. (1976) · Nature · doi:10.1038/263797a0 · Cited by 1,182
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912273 · Cited by 1,147
The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy
Doane, T. L., & Burda, C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15260f · Cited by 1,098
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Folate-mediated delivery of macromolecular anticancer therapeutic agents
Lu, Y., & Low, P. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00042-x · Cited by 941
Canton, I., & Battaglia, G. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15309b · Cited by 936
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
Applications of gold nanoparticles in cancer nanotechnology
Cai, W. (2008) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s3788 · Cited by 851
Strategies for the intracellular delivery of nanoparticles
Chou, L. Y. T., Ming, K., & Chan, W. C. W. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00003e · Cited by 811
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Theranostic Magnetic Nanoparticles
Yoo, D., Lee, J.-H., Shin, T.-H., & Cheon, J. (2011) · Accounts of Chemical Research · doi:10.1021/ar200085c · Cited by 730
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Choi, C. H. J., Alabi, C. A., Webster, P., & Davis, M. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914140107 · Cited by 699
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Lipid nanocapsules: A new platform for nanomedicine
Huynh, N. T., Passirani, C., Saulnier, P., & Benoit, J. P. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.026 · Cited by 595
Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M., & Gold, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2136683100 · Cited by 567
Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics
Klumpp, C., Kostarelos, K., Prato, M., & Bianco, A. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.10.008 · Cited by 540
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
Shi, J., Xiao, Z., Kamaly, N., & Farokhzad, O. C. (2011) · Accounts of Chemical Research · doi:10.1021/ar200054n · Cited by 476
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Receptor-targeted nanocarriers for therapeutic delivery to cancer
Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.521200 · Cited by 423
Nanotheranostics and image-guided drug delivery: current concepts and future directions
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100228v · Cited by 397
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Avgoustakis, K. (2004) · Current Drug Delivery · doi:10.2174/1567201043334605 · Cited by 382
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
PEGylated nanoparticles for biological and pharmaceutical applications
Otsuka, H., Nagasaki, Y., & Kataoka, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.022 · Cited by 358
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
Single-walled carbon nanohorns and their applications
Zhu, S., & Xu, G. (2010) · Nanoscale · doi:10.1039/c0nr00387e · Cited by 336
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z. (., & Shin, D. M. (2009) · Nanoscience and Technology · doi:10.1142/9789814287005_0025 · Cited by 321
Nanomaterials for Cancer Therapy and Imaging
Bae, K. H., Chung, H. J., & Park, T. G. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0051-5 · Cited by 313
Docetaxel for treatment of solid tumours: a systematic review of clinical data
Montero, A., Fossella, F., Hortobagyi, G., & Valero, V. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70094-2 · Cited by 311
Anticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy
Gindy, M. E., & Prud'homme, R. K. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902932908 · Cited by 298
Maresca, K. P., Hillier, S. M., Femia, F. J., Keith, D., Barone, C., Joyal, J. L., Zimmerman, C. N., Kozikowski, A. P., Barrett, J. A., Eckelman, W. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800994j · Cited by 295
Biomedical applications of functionalized fullerene-based nanomaterials
Conyers, J. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s5964 · Cited by 274
Folate-mediated delivery of macromolecular anticancer therapeutic agents
Lu, Y., & Low, P. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.020 · Cited by 266
Docetaxel-related side effects and their management
Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M. S., & von Minckwitz, G. (2009) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2008.10.003 · Cited by 261
Spatiotemporal controlled delivery of nanoparticles to injured vasculature
Chan, J. M., Zhang, L., Tong, R., Ghosh, D., Gao, W., Liao, G., Yuet, K. P., Gray, D., Rhee, J.-W., Cheng, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914585107 · Cited by 253
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Mamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244
The taxoids: paclitaxel and docetaxel
Gelmon, K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90754-4 · Cited by 243
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
Schülke, N., Varlamova, O. A., Donovan, G. P., Ma, D., Gardner, J. P., Morrissey, D. M., Arrigale, R. R., Zhan, C., Chodera, A. J., Surowitz, K. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1735443100 · Cited by 232
Nanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems
Badea, I., & Kaur, R. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s37348 · Cited by 226
NAAG peptidase inhibitors and their potential for diagnosis and therapy
Zhou, J., Neale, J. H., Pomper, M. G., & Kozikowski, A. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1903 · Cited by 222
Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxane
Singer, J. W. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.033 · Cited by 213
Ultrasound triggered, image guided, local drug delivery
Deckers, R., & Moonen, C. T. W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.117 · Cited by 190
Extravasation of polymeric nanomedicines across tumor vasculature
Danquah, M. K., Zhang, X. A., & Mahato, R. I. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.005 · Cited by 188
Aptamer-Functionalized Nanoparticles for Medical Applications: Challenges and Opportunities
Xiao, Z., & Farokhzad, O. C. (2012) · ACS Nano · doi:10.1021/nn301869z · Cited by 172
Cell-specific delivery of genes with glycosylated carriers
HASHIDA, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00209-5 · Cited by 171
Long-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet?
Taylor, A., Wilson, K. M., Murray, P., Fernig, D. G., & Lévy, R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35031a · Cited by 166
Tagami, T., Ernsting, M. J., & Li, S.-D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.009 · Cited by 166
Targeting tumor angiogenic vasculature using polymer–RGD conjugates
Mitra, A., Mulholland, J., Nan, A., McNeill, E., Ghandehari, H., & Line, B. R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.023 · Cited by 162
Sanna, V., Pintus, G., Roggio, A. M., Punzoni, S., Posadino, A. M., Arca, A., Marceddu, S., Bandiera, P., Uzzau, S., & Sechi, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1013715 · Cited by 157
Self-citationPEGylation strategies for active targeting of PLA/PLGA nanoparticles
Betancourt, T., Byrne, J. D., Sunaryo, N., Crowder, S. W., Kadapakkam, M., Patel, S., Casciato, S. L., & Brannon‐Peppas, L. (2008) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32247 · Cited by 155
Biodegradable Nanoparticles for Direct or Two-Step Tumor Immunotargeting
Bossy-Nobs, L., Buchegger, F., Gurny, R., & Allémann, É. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050137k · Cited by 139
How nanotechnology can enhance docetaxel therapy
Zhang, L., & Zhang, N. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s46921 · Cited by 125
Targeting of nanoparticles in cancer
Talekar, M., Kendall, J. D., Denny, W. A., & Garg, S. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834a4554 · Cited by 115
Improved therapeutic effect of folate-decorated PLGA–PEG nanoparticles for endometrial carcinoma
Liang, C., Yang, Y., Ling, Y., Huang, Y., Li, T. X., & Li, X. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.05.016 · Cited by 111
CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development
Young, C., Schluep, T., Hwang, J., & Eliasof, S. D. (2011) · Current Bioactive Compounds · doi:10.2174/157340711795163866 · Cited by 108
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
New approaches to antibody therapy
Weiner, L. M., & Adams, G. P. (2000) · Oncogene · doi:10.1038/sj.onc.1204000 · Cited by 88
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
Sankhala, K. K., Mita, A. C., Adinin, R., Wood, L. M., Beeram, M., Bullock, S., Yamagata, N., Matsuno, K., Fujisawa, T., & Phan, A. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2535 · Cited by 84
Carbon Nanomaterials: Efficacy and Safety for Nanomedicine
Yamashita, T., Yamashita, K., Nabeshi, H., Yoshikawa, T., Yoshioka, Y., Tsunoda, S., & Tsutsumi, Y. M. (2012) · Materials · doi:10.3390/ma5020350 · Cited by 81
Chandran, S. S., Banerjee, S. R., Mease, R. C., Pomper, M. G., & Denmeade, S. R. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.5968 · Cited by 74
Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers
Montana, M., Castera‐Ducros, C., Verhaeghe, P., Terme, T., Vanelle, P., & Rathelot, P. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.2.59 · Cited by 72
Dendrimers as Biopharmaceuticals: Synthesis and Properties
Villalonga‐Barber, C., Micha‐Screttas, M., Steele, B. R., Georgopoulos, A., & Demetzos, C. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608785849012 · Cited by 65
Clift, M. J. D., & Stone, V. (2012) · Theranostics · doi:10.7150/thno.4545 · Cited by 65
Role of Nanobiotechnology in the Development of Personalized Medicine
Jain, K. (2009) · Nanomedicine · doi:10.2217/nnm.09.12 · Cited by 63
Formulation/Preparation of Functionalized Nanoparticles for In Vivo Targeted Drug Delivery
Gu, F., Langer, R., & Farokhzad, O. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-483-4_37 · Cited by 56
Identification of cancer targets and therapeutics using phage display.
Brissette, R. E., Prendergast, J. K. A., & Goldstein, N. I. (2006) · PubMed · Cited by 53
Drug Targeting to Tumors: Principles, Pitfalls and (Pre-) Clinical Progress
Lammers, T., Kiessling, F. M., Hennink, W. E., et al. (2020) · doi:10.1201/9780429399039-6 · Cited by 43
Glycosylated carriers for cell-selective and nuclear delivery of nucleic acids
Wijagkanalan, W. (2011) · Frontiers in bioscience · doi:10.2741/3892 · Cited by 17
Byun, Y., Mease, R. C., Lupold, S. E., & Pomper, M. G. (2009) · doi:10.1002/9780470508169.ch36 · Cited by 7
Cited by
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
SERS Nanoparticles in Medicine: From Label-Free Detection to Spectroscopic Tagging
Lane, L. A., Qian, X., & Nie, S. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00265 · Cited by 873
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Metadata
- Authors
- Sechi, M., Sanna, V., & Pala, N.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2014-01
- Volume
- 9
- Pages
- 467
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1981412372
- Cited by
- 493
- References
- 130
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.